An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.
2018
TPS7076Background: Persistence of leukemic stem cells is an important cause of relapse in patients with acute myeloid leukemia (AML). CD123 (α-chain of the interleukin-3 receptor) is highly express...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
4
Citations
NaN
KQI